Clinical trials
Alcoholic Liver Disease clinical trials
Below are recruiting alcoholic liver disease clinical trials, each written for real people, not researchers. We’re tracking 256 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07068191Recruiting
Gepaktiv vs other drugs for fatty liver with enlarged liver
This study tests a new drug, Gepaktiv, compared to two other treatments (UDCA and ademetionine) for people with metabolic fatty liver disease who also have an enlarged liver. You may be able to join if you meet specific test results showing moderate liver fat and scarring.
Tyumen, Tyumen OblastAges 18–65 - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07093346Recruiting
Pectin supplement for fatty liver disease
This study tests whether a pectin supplement (a fiber found in fruits) can reduce inflammation and improve liver and metabolic health in people with fatty liver disease (MASLD). You might be eligible if you have MASLD, a healthy weight range, and can avoid certain medications and foods.
NottinghamAges 18 years+ - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75 - NCT07169526Recruiting
Health literacy and confidence in alcohol-related liver cirrhosis
This study looks at how well patients with alcohol-related liver cirrhosis understand health information and feel confident managing their health. It aims to find ways to support patients better.
HanoverAges 18–99 - NCT07193927RecruitingPhase 2
Testing a probiotic mix for fatty liver disease (MASLD)
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
Girona, GironaAges 18–75 - NCT07241195Recruiting
Fatty Liver Study in Older Adults
This study follows older adults with fatty liver disease to understand how their metabolism changes over time and how it affects their overall health. It helps researchers learn more about the condition and its impact on the body outside the liver.
Hangzhou, ZhejiangAges 65–100 - NCT07265544Recruiting
Liver disease study using advanced tissue analysis
This study uses advanced techniques to analyze liver tissue samples from people with various liver conditions. It aims to better understand how liver diseases develop and progress, which may help improve future treatments.
Guangzhou, GuangdongAges Any age - NCT07270601Recruiting
Ultrasound test for liver fat
This study is testing a new ultrasound method to measure fat in the liver. It is for people who may have a liver condition or have risk factors like diabetes or obesity, as well as healthy volunteers.
Seattle, WashingtonAges 18–75 - NCT07294963Recruiting
Lifestyle changes to help thinking and memory in fatty liver disease
This trial tests whether lifestyle changes can prevent cognitive decline in people with non-alcoholic fatty liver disease. If you have fatty liver and are between 18 and 42 years old, you may be able to join.
Peshawar, KPKAges 18–42 - NCT07308548RecruitingPhase 2
Testing HP515 for fatty liver disease (NASH/MASH)
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT02037867Recruiting
Study your liver blood markers if you’re at risk
This study looks at how certain blood tests (liver biomarkers) change in people with higher risk for liver disease. It may help doctors understand who is developing liver problems earlier and what patterns in blood tests matter most.
Nottingham, NottsAges 18 years+ - NCT05699018Recruiting
Screening people with liver scarring in primary care
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
AngersAges 40–80 - NCT07525258Recruiting
Improving alcohol use disorder care for liver disease patients
This trial tests a new approach to help healthcare providers better support patients with alcohol-related liver disease who struggle with alcohol use. The study aims to make treatment easier to access and more effective within Yale's hospital system.
New Haven, ConnecticutAges 18 years+ - NCT07553663RecruitingPhase 1
Testing a new liver disease treatment for fatty liver
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
San Antonio, TexasAges 18–75 - NCT07658755Recruiting
LiverSeek: Finding advanced liver scarring in MASLD
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Madrid, MadridAges 50–75 - NCT07564947Enrolling by invitation
Reishi Mushroom for Fatty Liver Disease
This study tests whether Ganoderma lucidum (reishi mushroom) can improve liver health and reduce inflammation in people with fatty liver disease. Researchers will measure how it affects your liver function and antioxidant levels.
Peshawar, Khyber PakhtunkhwaAges 35–49 - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT06942312Enrolling by invitation
Liver metabolism study in non-alcoholic fatty liver disease
This trial studies how the liver processes fat in people with non-alcoholic fatty liver disease (NAFLD). It uses MRI scans to look at liver metabolism, which may help doctors understand the disease better and find new treatments.
Helsinki, UusimaaAges 18–75 - NCT06888570Enrolling by invitation
Liver health study for children & young adults with Down syndrome
This study looks at how eating patterns and body composition relate to fatty liver in children and young adults with Trisomy 21 (Down syndrome) or other genetic intellectual disabilities. It may help understand who is at risk and how to prevent liver problems.
Madrid, MadridAges 5–22 - NCT06840652Enrolling by invitation
Baclofen for alcohol withdrawal in liver disease
This trial tests if baclofen, a medicine for alcohol dependence, is safe and works for people with chronic liver disease who are actively drinking. It may help you stop drinking alcohol safely.
Sabadell, BarcelonaAges 18–75 - NCT06838468Enrolling by invitation
Study on liver health in alcohol detox patients
This study is looking at liver health in people staying in a detox unit for alcohol use disorder. Researchers want to see how common liver problems are in this group. Participating involves extra tests like blood work, an ultrasound, and a special liver scan (FibroScan).
Sabadell, BarcelonaAges 18–75 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75
Hear when a new Alcoholic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alcoholic liver disease?
- Yes. Clin2 currently lists 256 recruiting alcoholic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alcoholic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alcoholic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.